Skip to content

Role of Shampakadi Asthapana Basti with Patrapinda Sweda and Erandamooladi Niruha Basti with Patrapinda Sweda in Gridhrasi or Sciatica.

An open label randomized study to compare the efficacy of Shampakadi Asthapana Basti and Patrapinda Sweda with Erandamooladi Niruha Basti and Patrapinda Sweda In the management of Gridhrasi visa-A-vis Sciatica. - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/08/092736
Enrollment
30
Registered
2025-08-11
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M543- Sciatica

Interventions

None listed

Sponsors

Dr Manoj k p
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects fulfilling the diagnostic criteria of Gridhrasi ( Sciatica ). Subjects between the age group of 21 - 60 years irrespective of gender, religion, occupation and socioeconomic status. Subjects fit for Basti Karma and Patrapinda Sweda. Subjects presenting with clinical signs and symptoms of Gridhrasi. Subjects who are willing to give a written consent for the treatment.

Exclusion criteria

Exclusion criteria: Subjects below 21 years and above 60 years of age. Subjects unfit for Basti Karma and Patrapinda Sweda. Systemic diseases which interfere with the course of treatment will be excluded. Subjects with spinal deformity, severe traumatic condition like compressive fractures, Quada equina compression, tuberculosis of the spine or any infective and inflammatory diseases of spine , benign or malignant tumors of spine ,Post-surgical conditions of lumbar spine,AVN of head of femur. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
PRIMARY OUTCOME: Significant reduction in symptoms of Gridhrasi (Sciatica) as assessed based on subjective and objective parameters. Timepoint: 0th, 10th, 30th day

Secondary

MeasureTime frame
SECONDARY OUTCOME: Generation of data on adverse effect of drug or event if any. Generation of in-depth analysed data on the different aspect of the disease. To assess the effect of therapy on the quality of life based on Oswestry Disability Index scale. Timepoint: Trial period 10 days Initial assessment 0th day Assessment on - 10th day Follow up - 30th day Total study duration - 30 day.

Countries

India

Contacts

Public ContactDr Prarthana T

Sri Sri College Of Ayurvedic Science and Research hospital

drprarthana88@gmail.com9513180577

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026